1	Major depressive disorder but not bipolar disorder and schizophrenia is a causal factor						
2	for type 2 diabetes as determined by Mendelian randomization						
3							
4	Short title: Psychiatric disorders and type 2 diabetes risk						
5							
6	Heejin Jin, M.S. ^{1,2} , Jeewon Lee, M.D., Ph.D. ³ , Sohee Oh, Ph.D. ² , Sanghun Lee, Ph.D. ^{4*} ,						
7	Sungho Won, Ph.D. ^{1,5*}						
8	¹ Department of Public Health Science, Seoul National University, Seoul, Korea						
9	² Medical Research Collaborating Center, Department of Biostatistics, Seoul Nationa						
10	University Boramae Hospital, Seoul, Republic of Korea						
11	³ Department of Psychiatry, Soonchunhyang University Bucheon Hospital, Bucheon, Republic						
12	of Korea						
13	⁴ Department of Medical Consilience, Graduate School, Dankook University, Yongin-si,						
14	Republic of Korea						
15	⁵ Institute of Health and Environment, Seoul National University, Seoul, South Korea.						
16							
17	* Correspondence:						
18 19 20	Sungho Won, Department of Public Health Science, Seoul National University 1 Kwanak-ro Kwanak-gu Seoul 151-742 Korea (Email) won1@snu.ac.kr, (Tel) +82-2-880-2714, (Fax) +82-303-0942-2714						
21 22 23 24 25	Sanghun Lee, Department of Medical Consilience, Graduate School, Dankook University, 126-0 Suji-gu Yongin-si Gyeonggi-do Korea (Email) sanghunlee73@gmail.com, (Tel) +82-10-2602-3759						
26	Word count: 3,688						
27	Number of tables and figures: 3 tables and 1 figure						
28							

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 ABSTRACT

Objective: In many epidemiologic studies, type 2 diabetes has been reported to be associated with severe mental illness (SMI) such as schizophrenia (SCZ), bipolar disorder (BPD), and major depressive disorder (MDD). However, the relationship between SMI and type 2 diabetes is bi-directional, and the causal relationship remains unclear due to various confounders. Therefore, a Mendelian randomization (MR) study is necessary to identify the causality between them.

36 Research Design and Methods: We conducted a two-sample MR study to identify the causal 37 effect of SMI on type 2 diabetes using the inverse-variance weighted (IVW), MR-Egger, MR-38 Egger with a simulation extrapolation, weighted median approach, and MR-Pleiotropy 39 RESidual Sum and Outlier methods. The most appropriate method was selected according to 40 the instrument variables assumption.

41Results: We found that MDD had a significant causal effect on type 2 diabetes from the results42obtained using the IVW method (Odds ratio (OR): 1.191, 95% CI: 1.036–1.372, P = 0.014);43however, this was not observed for BPD (IVW, OR: 1.006, 95% CI: 0.918–1.104, P = 0.892)44or SCZ (IVW, OR: 1.016, 95% CI: 0.974–1.059, P = 0.463). The absence of reverse-causality45between MDD and type 2 diabetes was also demonstrated from bi-directional MR studies.

46 Conclusions: These results clearly reveal important knowledge on the causal role of MDD in
47 the risk of type 2 diabetes without a residual confounding, whereas the causality of BPD and
48 SCZ was not shown. Therefore, careful attention should be paid to MDD patients in type 2
49 diabetes prevention and treatment.

50

52 **INTRODUCTION**

53 To date, many epidemiologic studies have suggested the link between type 2 diabetes 54 and severe mental illness (SMI) including bipolar disorder (BPD), major depressive disorder 55 (MDD), and schizophrenia (SCZ) (1). The prevalence of type 2 diabetes among individuals 56 with SMI has been estimated to be 8% to 17% in BPD, and 16% to 25% in SCZ; further, depressed adults have a 37% increased risk of developing type 2 diabetes (2-4). The side effects 57 58 of the medication used for treating SMI, unhealthy lifestyle behaviors of patients with SMI, 59 and hypothalamic-pituitary-adrenal (HPA) axis dysregulation could contribute to the 60 association of SMI with type 2 diabetes (5; 6). For instance, medications such as antipsychotics, 61 antidepressants, and mood stabilizers are likely to contribute to type 2 diabetes development 62 by leading to insulin resistance or weight gain (1). Moreover, low physical activity, poor diet, 63 smoking, alcohol, and substance abuse in individuals with SMI might lead to type 2 diabetes 64 (7).

65 In contrast, type 2 diabetes also affects mental health. One meta-analysis indicated that the risk of MDD increases in people with type 2 diabetes (8), and a prospective population-66 67 based study showed that the prevalence of schizophrenia was significantly higher in patients with type 2 diabetes than in the general population (9). Further, a cross-sectional study reported 68 69 that type 2 diabetes and prediabetes may be risk factors in patients with BPD (10). Large 70 longitudinal studies have also demonstrated that type 2 diabetes impacts mental health 71 negatively (11). As the results of epidemiological studies are inconsistent, the true causality 72 between SMI and type 2 diabetes is still unclear with potential biases and confounding factors. 73 Moreover, the difference between the onset age of type 2 diabetes and SMI makes it very 74 challenging to infer a causal relationship. In general, type 2 diabetes affects middle-aged adults 75 (after age 40) with low heritability (10–15%), while SMI usually occurs in young adulthood 76 (in the 20–30s) with high heritability (80–85% for BPD, 80% for SCZ, and 31–42% for MDD)

(12; 13). Accordingly, we hypothesized that SMI would precede type 2 diabetes, if there is a
causal effect between them.

79 Therefore, well-designed, two-sample Mendelian randomization (MR) studies, which 80 have widely been adopted using genetic variants such as single nucleotide polymorphisms 81 (SNP) for instrumental variable (IV) analysis are needed to pinpoint the causal relationship 82 between SMI and type 2 diabetes (14). Compared to a one-sample MR, two-sample MR will 83 not lead to inflated type 1 error rated and false-positive findings. To the best of our knowledge, 84 a two-sample MR analysis focusing on SMI and type 2 diabetes is currently lacking. For this 85 purpose, robustness against potential confounders in MR analysis can be achieved if the three 86 core assumptions for IV, including strong association with intermediate exposure, 87 independence with confounders, and no direct path for the outcome are satisfied. We 88 considered several MR approaches including an inverse-variance weighted (IVW) method and 89 sensitivity analyses-MR-Egger, MR-Egger with a simulation extrapolation (SIMEX), 90 weighted median approach, and MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) 91 method—in the case of violation of the assumptions (15).

Here, we investigate the causality between SMI and type 2 diabetes using genomewide summary statistics in a meta-analysis of a large population of European individuals through two-sample MR study.

95

96 RESEARCH DESIGN AND METHODS

97 Exposure dataset: summary statistics of genetic association analyses with bipolar
98 disorder

SNPs-BPD associations were obtained from 20,352 cases and 31,358 controls who
lived in 14 countries in Europe, North America, and Australia (16). Cases were required to

101 meet international consensus criteria (diagnostic and statistical manual of mental disorders 102 (DSM-IV), internatinal classification of diseases (ICD)-9, or ICD-10) for a lifetime diagnosis of BPD established using structured diagnostic instruments from assessments by trained 103 104 interviewers, clinician-administered checklists, or medical record reviews. A total of 9,372,253 105 SNPs were used for genome-wide association (GWA) analyses; among these, 16 genome-wide significant ($P < 5 \times 10^{-08}$) SNPs associated with BPD were identified after linkage 106 disequilibrium (LD) pruning (distance < 10,000 kb or LD $r^2 < 0.001$). After removal of SNPs 107 nominally associated with type 2 diabetes (P < 0.05), 11 BPD-associated SNPs were available. 108 109

110 Exposure dataset: summary statistics of genetic association analyses with major 111 depressive disorder

112 The summary statistics for association between SNPs-MDD were obtained through 113 large-scale genome-wide association meta-analyses of 807,553 individuals (246,363 cases and 114 561,190 controls) from the UK Biobank, 23andMe, Inc., and psychiatric genomics consortium 115 (PGC) (17). The definition of MDD was different in each cohort. In the UK Biobank, three 116 MDD phenotypes were used; 1) self-reported help-seeking for problems with nerves, anxiety, 117 tension, or depression, 2) self-reported depressive symptoms, and 3) MDD identified from 118 hospital admission records. In case of 23andMe, Inc., a self-reported clinical diagnosis of 119 depression was used. Finally, cases were required to meet international consensus criteria 120 (DSM-IV, ICD-9, or ICD-10) in PGC. A total of 8,098,588 SNPs were combined for meta-121 analysis and 50 SNPs were selected as candidates of IVs. None of them were in the same LD block ($r^2 < 0.001$) or within 10,000 kb of an established signal. We checked the pleiotropic 122 123 effect of those SNPs, and eight SNPs associated with type 2 diabetes (P < 0.05) were eliminated. 124 Thus, 42 MDD-associated SNPs were used for our analyses.

126 Exposure dataset: summary statistics of genetic association analyses with schizophrenia

127 SNPs-SCZ associations were obtained from 33,640 cases and 43,456 controls from the 128 PGC (18). Cases with clinical diagnosis (not self-report) of SCZ or schizoaffective disorder 129 were included in our study. Summary statistics of GWA analyses for 13,942,226 SNPs were 130 available, and 83 variants that were genome-wide significantly associated with schizophrenia 131 were significant after LD pruning (distance < 10,000 kb or LD r^2 < 0.001). Eleven SNPs were 132 associated with type 2 diabetes (P < 0.05), and the remaining 72 SCZ-associated SNPs were 133 used for our MR analyses.

134

135 Outcome dataset: summary statistics of genetic association analyses with type-2 diabetes

We obtained summary statistics for associations between SNPs-type 2 diabetes from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium stage 1 metaanalyses with 26,676 cases and 132,532 controls (19). Type 2 diabetes diagnosis was based on diagnostic fasting glucose ($\geq 7 \text{ mmol/L}$) or HbA1c levels ($\geq 6.5\%$), hospital discharge diagnosis, use of oral diabetes medication, or self-report. Summary statistics of GWA analyses for 12.1 million SNPs were available and were considered for our MR analyses.

142

143 Mendelian randomization analysis

All SNPs associated with BPD, MDD, or SCZ were selected separately as candidates of IVs that had genome-wide significance and were not in a LD block ($r^2 < 0.001$) or within 10000 kb of an established signal. *F*-statistics provided an indication of instrument strength and *F* > 10 indicated that the analysis was unlikely to suffer from weak instrument bias (20). A degree of violation of the "NO Measurement Error" (NOME) assumption was quantified using l^2 statistics and $l^2 > 90$ indicated lesser dilution of the estimates in MR analysis (21). For the detection of pleiotropic outlier SNPs, Cochran's Q-test in the inverse-variance weighted (IVW)

151 method and Rucker Q' statistics in the MR-Egger were used (22). We further conducted an MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) test as an indicator of no violations 152 of MR assumptions in the final IV sets (23). Given that no weak instrument bias (F > 10) was 153 154 observed and the three tests (Cochran's Q-test, Rucker Q'test, and MR-PRESSO test) indicated 155 no directional pleiotropic bias, the IVW method was applied, which is robust when all SNPs 156 are valid instruments (15). Here "valid" means that the following three conditions are satisfied: (i) IVs are strongly associated with exposure, (ii) IVs independent of confounders, and (iii) IVs 157 158 do not affect the outcome directly. If we assume instruments-outcome association and exposure-outcome association are denoted by β_{GY} and β_{XY} , respectively, then the IVW 159 160 estimate of causal effect (i.e., effect of the exposure on the outcome) can be obtained from the 161 inverse-variance weighted mean of ratio estimates (β_{GY}/β_{XY}). If the pleiotropy and outlier SNPs were detected from MR-PRESSO, IVW is not recommended, and we consider several 162 163 sensitivity analyses to minimize bias. Weighted median method provides valid causal estimates 164 unless more than 50% of the instruments are invalid (15). MR-Egger method can estimate 165 appropriate causal effects in the presence of pleiotropy effects even if all SNPs are invalid (15). 166 When Cochran's Q-test is rejected or both Cochran's Q and Rucker Q' tests are rejected, the 167 MR-Egger method is recommended (15). If the measurement error of the instruments is large $(I^2 > 90)$, the method of SIMEX was applied to correct attenuation bias (21). Furthermore, we 168 conducted a bi-directional MR to investigate the presence of reverse-causality between SMI 169 170 and type 2 diabetes. The Šidák correction for multiple comparisons was used for analysis and thus, threshold of P of $1-(1-0.05)^{\frac{1}{3}} = 0.017$ (24). Observed power (or post-hoc power) 171 172 calculations were performed using the online tool (https://sb452.shinyapps.io/power/) (25). The proportion of variance in the exposure explained by the genetic variants (R^2) were required 173 for MR power analysis, and 0.23 (BPD), 0.089 (MDD), 0.24 (SCZ), and 0.196 (type 2 diabetes) 174 175 were used.

176 **RESULTS**

177 Effect of bipolar disorder on type 2 diabetes

178 Eleven SNPs that genome-wide significantly associated with BPD but not type 2 179 diabetes were used as instrument variables. All SNP-exposure and SNP-outcome effects are 180 presented in Supplementary Table 1. We found no evidence of weak instrument bias (F-statistic 181 = 32.9), and heterogeneity and outlier pleiotropy were not observed (O-test, P = 0.718; O'-test, P = 0.821; MR-PRESSO global test, P = 0.695) (Table 1). The MR-Egger test also indicated 182 no directional pleiotropic bias (intercept P = 0.165) and there was no violation of the NOME 183 assumption ($I^2 = 96.9\%$) (Table 1). Since all IV assumptions were satisfied, the IVW method 184 was considered to be the most appropriate to provide unbiased estimate (15; 22). IVW showed 185 non-significant effect on the type 2 diabetes (odds ratio (OR): 1.006, 95% CI: 0.918–1.104, P 186 = 0.892). The post-hoc statistical power estimated using OR was 2.5%. Non-significant results 187 188 were also obtained from other sensitivity analyses (MR-Egger, OR: 0.681, 95% CI: 0.389-189 1.191, P = 0.178; MR-Egger (SIMEX), OR: 0.995, 95% CI: 0.908–1.089, P = 0.917; weighted 190 median, OR: 0.982, 95% CI: 0.868-1.111, P = 0.770) (Table 2). We checked the reverse-causal 191 association between BPD and type 2 diabetes with the 35 SNPs associated with type 2 diabetes. 192 There was no weak instrument bias (F-statistic = 35.8) and no violation of the NOME assumption ($I^2 = 97.3\%$). No evidence of heterogeneity was found from the Q-test (P = 0.684), 193 O'-test (P = 0.639), and MR-PRESSO global test (P = 0.598) (Table 1). Non-significant 194 195 reverse-causal effect was found (IVW, OR: 1.031, 95% CI: 0.971–1.095, P = 0.313; MR-Egger, 196 OR: 1.051, 95% CI: 0.793–1.394, P=0.727; MR-Egger (SIMEX), OR: 0.993, 95% CI: 0.909– 1.083, P = 0.867; weighted median OR: 1.041, 95% CI: 0.956–1.134, P = 0.349) (Table 3). 197 198 The associations of the variants with BPD and type 2 diabetes are shown in a scatter plot with 199 four MR-fitted lines (Figure 1A).

201 Effect of major depressive disorder on type 2 diabetes

202 Forty-two independent SNPs that associated with MDD but not type 2 diabetes were 203 used as IVs. All SNP-exposure and SNP-outcome effects are presented in Supplementary Table 204 2. Weak instrument assumption was guaranteed by F-statistic (37.9) and there was no measurement error of estimates from the MR study ($l^2 = 97.3\%$). No evidence of heterogeneity 205 206 or pleiotropy was confirmed through the Q-test (P = 0.808), Q'-test (P = 0.788), and MR-PRESSO global test (P = 0.733) (Table 1). Since all IV assumptions were satisfied, the IVW 207 method was chosen and showed significant results (OR: 1.191, 95% CI: 1.036–1.372, P =208 209 0.014). The post-hoc statistical power estimated from the ORs was 100%. Among the other 210 sensitivity analyses, MR-Egger (SIMEX) showed a consistent significant result (OR: 1.162, 211 95% CI: 1.024–1.318, P = 0.025) and weighted median showed a nominally significant (P < 1000212 0.1) result (OR: 1.196, 95% CI: 0.984–1.453, P = 0.072). Non-significant result of MR-Egger may be attributable to the low power of ME-Egger (OR: 0.934, 95% CI: 0.402–2.172, P =213 214 0.875) (Table 2). To check the reverse-causal effect, 39 variants were used as instruments. We found that all assumptions for MR analyses were preserved (F-statistic = 36.0; Q-test, P =215 0.714; Q'-test, P = 0.683; MR-PRESSO global test, P = 0.711; $I^2 = 97.3\%$) (Table 1). Non-216 significant reverse-causal effect was found (IVW, OR: 1.002, 95% CI: 0.985-1.020, P = 0.793; 217 218 MR-Egger, OR: 1.008, 95% CI: 0.949–1.070, P = 0.798; MR-Egger (SIMEX), OR: 1.002, 95% 219 CI: 0.985-1.019, P = 0.808; weighted median, OR: 1.007, 95% CI: 0.982-1.134, P = 0.581) 220 (Table 3). The associations of the variants with MDD and type 2 diabetes are shown in a scatter plot with four MR-fitted lines (Figure 1B). 221

222

223 Effect of schizophrenia on type 2 diabetes

224 Seventy-two independent SNPs that associated with SCZ, but not type 2 diabetes were 225 found to have strong instrument strength (*F*-statistic = 41.5) and non-significant heterogeneity

226 and outlier pleiotropy (Q-test, P = 0.319; Q'-test, P = 0.290; MR-PRESSO global test, P =227 0.704) (Table 1). All SNP-exposure and SNP-outcome effects are presented in Supplementary Table 3. In addition, there was no dilution bias from violation of the NOME assumption (l^2 = 228 97.2%). The IVW method was the most powerful and showed a non-significant result (OR: 229 230 1.016, 95% CI: 0.974-1.059, P = 0.463). The post-hoc statistical power by estimated ORs was 231 10.9%. The other sensitivity analyses results showed a non-significant effect of SCZ on type 2 diabetes (MR-Egger, OR: 1.012, 95% CI: 0.851–1.204, P = 0.888; MR-Egger (SIMEX), OR: 232 233 1.015, 95% CI: 0.981-1.060, P = 0.511; weighted median, OR: 1.016, 95% CI: 0.955-1.081, P = 0.615) (Table 2). To detect reserve-causal effect, forty-three SNPs were used as instruments. 234 235 *F*-statistic showed no weak instrument bias (*F*-statistic = 35.8) and no violation of the NOME assumption $(l^2 = 97.2)$ (Table 1). Heterogeneity test showed substantial evidence of outlier 236 pleiotropy using the Q-test (P < 0.001), Q'-test (P < 0.001), and MR-PRESSO global test (P < 0.001) 237 238 0.001) (Table 1). Since all three tests were rejected, the MR-PRESSO method was adopted (15) 239 after excluding the two outlier SNPs (OR: 0.999, 95% CI: 0.991-1.009, P = 0.987), suggesting 240 non-significant effect of type 2 diabetes on SCZ. The associations of the variants with SCZ and 241 type 2 diabetes are shown in a scatter plot with four MR-fitted lines (Figure 1C).

242

243 CONCLUSIONS

In the present study, two-sample MR results provided solid evidence in support of the hypothesis that MDD increases the risk of type 2 diabetes, whereas BPD and SCZ were not identified as risk factors for type 2 diabetes. Bi-directional MR study also confirmed that there was no reverse-causality between SMI and type 2 diabetes, and the asymmetry in the effects of the instruments on type 2 diabetes and MDD supports the fact that MDD is one of the causal factors that influences type 2 diabetes. However, causal effects of MDD on type 2 diabetes development have been demonstrated to be controversial in observational studies. One

systematic review demonstrated that MDD is associated with a 60% increased risk of type 2 diabetes, while the evidence is also compatible with the high prevalence rates of MDD among individuals with type 2 diabetes (27). A large meta-analysis showed that type 2 diabetes is associated with only a modestly increased risk of MDD (28). MDD is difficult to detect in older adults which may partially explain why this association was so modest (29).

256 Our finding, the causal role of MDD in increased risk of type 2 diabetes, could be 257 explained by the pathophysiological mechanisms underlying the two diseases. Two major 258 molecular mechanisms have been suggested to explain the causal pathway between them. First, 259 the HPA axis, a central stress response system is commonly activated in MDD patients 260 suffering from emotional stressors, leading to a rise in the levels of glucocorticoids, primarily 261 cortisols (30). High cortisol level induces and aggravates insulin resistance in a vicious cycle, 262 such as increased β -cell function and increased insulin release to glucose challenge by 263 exacerbating progression to insulin resistance (31). Second, the sympathetic nervous system 264 (SNS) activity is also elevated in MDD (32). The SNS axis interacts complexly with the HPA 265 axis to maintain homeostasis during stress, resulting in an increased release of cortisol and other glucocorticoids, catecholamines, growth hormone, and glucagon. Indeed, the 266 267 catecholamines have marked metabolic effects, particularly on glucose metabolism (33).

268 However, our findings are inconsistent with some observational study suggesting a 269 causal role of BPD and SCZ in the risk of type 2 diabetes and that type 2 diabetes predicts the 270 development of MDD (3). Such associations may have been driven by residual confounding, 271 because many aspects of the relationship between SMI and type 2 diabetes are yet to be 272 examined in a controlled manner, and there are many suggestive evidences that can act as 273 confounders. First, sedentary lifestyle and low physical activity, which have been demonstrated 274 to be strongly associated with SMI, may play a role as a potential confounder (1). A large meta-275 analysis of general population studies reported that sedentary behavior is independently

276 associated with an increased risk of type 2 diabetes (34). In addition, side effects of medication 277 could also be another important potential confounder. A systematic review of cross-sectional and prospective studies of psychotropic medications and physical diseases indicated that the 278 279 use of antipsychotics, antidepressants, and mood stabilizers can contribute to an increased BMI 280 which is a major risk factor for type 2 diabetes (35). Especially, antipsychotics, such as 281 clozapine and olanzapine; antidepressants, such as paroxetine; and mood stabilizers, such as 282 lithium and valproate have been associated with increasing obesity. Further, the prevalence of 283 smoking behaviors (daily smoking) was the highest in SCZ, followed by BPD and MDD 284 compared with the general population and the association with smoking is very strong in SCZ 285 and BPD, while it is less strong in MDD (36). The evidence that nicotine addiction begins 286 before any of these SMIs develop suggests that there are shared genes associated with nicotine 287 addiction and SMI (37).

288 MR studies on the association between SMI and type 2 diabetes are scarce, with no 289 studies on BPD with type 2 diabetes. To investigate the potential causal relationship of type 2 290 diabetes with MDD, MR analysis was performed with a large longitudinal cohort from 2011 to 291 2013 in China (38). Genetic risk scores for type 2 diabetes were chosen as the instruments and 292 two-stage multiple regression was used for statistical analysis. The results provided evidence 293 of a potential causal effect of type 2 diabetes on MDD, which is the opposite of our results. We 294 thought that there is a finite-sample bias in the existing research, because in a one-sample 295 setting, the fitted values from the first-stage regression are correlated with the outcome in finite 296 samples even in the absence of a causal effect (39). Regarding the MR studies of SCZ and type 297 2 diabetes, two-sample MR was performed using the IVW and MR-Egger methods in 298 Europeans, East Asians, and trans-ancestry groups (40). No evidence of a causal role of type 2 299 diabetes for SCZ was observed in any of the analyses, which is consistent with our findings; 300 however, they did not perform bi-directional analysis for causal effect of SCZ on type 2

diabetes. Unlike epidemiological studies, the previous and the present MR studies could not consider multi-episode status of disease, which may have led to non-significant results of SCZ and BPD. This could be because multi-episode (versus first-episode) persons with SMI were significantly more likely to have type 2 diabetes than matched controls in the meta-analysis of observational studies (1).

306 Several limitations of our study need to be acknowledged. First, there are different 307 clinical subtypes of MDD (melancholic, psychotic, atypical, or undifferentiated) and bipolar 308 disorder (type 1 or 2) and mood states (manic, depressive, mixed, or euthymic); however, a 309 large category of diseases was analyzed without distinction. Second, although we conducted bi-directional MR studies, the sample size of GWA studies for instruments and BPD/SCZ (less 310 311 than 100,000) was relatively small, which could lead to low power of the analysis. Third, we 312 only included European population; hence, it is difficult to apply the same clinical 313 interpretation to other races. Nevertheless, the present study has implications in that the well-314 designed, two-sample MR study for SMI and type 2 diabetes produced less biased results than 315 those of the existing epidemiological studies or one-sample MR study. In addition, the present 316 study clearly showed the causality of MDD on type 2 diabetes, which is supported by 317 previously reported underlying biological mechanisms. Therefore, it is imperative to consider screening for diabetes and metabolic abnormalities in patients with MDD or probable MDD. 318

319

320 ACKNOWLEDGEMENTS

This work was supported by the Industrial Core Technology Development Program (20000134) funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea), and the National Research Foundation of Korea (2017M3A9F3046543). The authors declare that the

- 324 research was conducted in the absence of any commercial or financial relationships that could
- 325 be construed as a potential conflict of interest.

327 AUTHOR CONTRIBUTIONS

328 H.J. analyzed and interpreted the results and wrote the manuscript. J.L and S.O contributed to

329 discussion. S.W. and S.L. designed the study. All authors revised this paper critically for

- 330 important intellectual content.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.12.20193060; this version posted September 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

345 REFERENCES

- 346 1. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S,
- 347 Gaughran F, Lally J, Stubbs B. Diabetes mellitus in people with schizophrenia, bipolar disorder
- 348 and major depressive disorder: a systematic review and large-scale meta-analysis. World 349 Psychiatry 2016;15:166-174
- 350 2. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 351 352 2000;26:903-912
- 353 3. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased
- 354 prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and 355 schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70:19-
- 356 26
- 357 4. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid 358 depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069-1078
- 359 5. Vancampfort D, Mitchell AJ, De Hert M, Sienaert P, Probst M, Buys R, Stubbs B. Type 2
- diabetes in patients with major depressive disorder: a meta-analysis of prevalence estimates 360 361 and predictors. Depress Anxiety 2015;32:763-773
- 362 6. Enger C, Jones ME, Kryzhanovskaya L, Doherty M, McAfee AT. Risk of developing
- diabetes and dyslipidemia among adolescents with bipolar disorder or schizophrenia. Int J 363 364 Adolesc Med Health 2013;25:3-11
- 7. Scott D, Happell B. The high prevalence of poor physical health and unhealthy lifestyle 365 behaviours in individuals with severe mental illness. Issues Ment Health Nurs 2011;32:589-366 367 597
- 368 8. Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, Pouwer F, European
- 369 Depression in Diabetes (EDID) Research Consortium. Type 2 diabetes mellitus as a risk factor
- 370 for the onset of depression: a systematic review and meta-analysis. Diabetologia 2010;53:2480-
- 2486 371
- 372 9. Huang CJ, Hsieh HM, Tu HP, Jiang HJ, Wang PW, Lin CH. Schizophrenia in type 2 diabetes 373 mellitus: prevalence and clinical characteristics. Eur Psychiatry 2018;54:102-108
- 374 10. Hajek T, Calkin C, Blagdon R, Slaney C, Alda M. Type 2 diabetes mellitus: a potentially 375 modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol Psychiatry 2015;77:295-303 376
- 377 11. Feng X, Astell-Burt T. Impact of a type 2 diabetes diagnosis on mental health, quality of
- 378 life, and social contacts: a longitudinal study. BMJ Open Diabetes Res Care 2017;5: e000198
- 379 12. Consortium IS: Common polygenic variation contributes to risk of schizophrenia that 380 overlaps with bipolar disorder. Nature 2009;460:748-752
- 13. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review 381 382 and meta-analysis. Am J Psychiatry 2000;157:1552-1562
- 383 14. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental
- 384 variables in Mendelian randomization: comparison of allele score and summarized data 385 methods. Stat Med 2016;35:1880-1906
- 386 15. Jin H, Lee S, Won S. Causal evaluation of laboratory markers in type 2 diabetes on cancer
- 387 and vascular diseases using various Mendelian randomization tools. medRxiv 388 2020:2020.08.21.20179622
- 389 16. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, Mattheisen M, Wang
- 390 Y, Coleman JR, Gaspar HA, de Leeuw CA. Genome-wide association study identifies 30 loci
- 391 associated with bipolar disorder. Nat Genet 2019;51:793-803
- 392 17. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, Coleman JR,
- 393 Hagenaars SP, Ward J, Wigmore EM, Alloza C. Genome-wide meta-analysis of depression

- 394 identifies 102 independent variants and highlights the importance of the prefrontal brain 395 regions. Nat Neurosci 2019;22:343-352
- 18. Lam M, Chen CY, Li Z, Martin AR, Bryois J, Ma X, Gaspar H, Ikeda M, Benyamin B, 396
- 397 Brown BC, Liu R. Comparative genetic architectures of schizophrenia in East Asian and
- 398 European populations. Nat Genet 2019;51:1670-1678
- 399 19. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, Pervjakova N, Pers TH,
- 400 Johnson AD, Eicher JD, Jackson AU. An expanded genome-wide association study of type 2 401 diabetes in Europeans. Diabetes 2017;66:2888-2902
- 402 20. Burgess S, Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak
- 403 instruments in Mendelian randomization studies. Int J Epidemiol 2011;40:755-764
- 404 21. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. 405 Assessing the suitability of summary data for two-sample Mendelian randomization analyses 406
- using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol 2016;45:1961-1974
- 407 22. Bowden J, Spiller W, Del Greco M F, Sheehan N, Thompson J, Minelli C, Davey Smith G. 408 Improving the visualization, interpretation and analysis of two-sample summary data 409 Mendelian randomization via the Radial plot and Radial regression. Int J Epidemiol
- 410 2018;47:1264-1278
- 411 23. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in
- 412 causal relationships inferred from Mendelian randomization between complex traits and 413 diseases. Nat Genet 2018;50:693-698
- 414 24. Šidák Z. Rectangular confidence regions for the means of multivariate normal distributions. 415 J Am Stat Assoc 1967;62:626-633
- 416 25. Burgess S, Smith GD, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP, Holmes
- 417 MV, Minelli C, Relton CL. Guidelines for performing Mendelian randomization investigations.
- 418 Wellcome Open Research 2020;4:186
- 419 26. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
- 420 effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512-421 525
- 422 27. Lustman PJ, Griffith LS, Clouse RE, Cryer PE. Psychiatric illness in diabetes mellitus. 423 Relationship to symptoms and glucose control. J Nerv Ment Dis 1986; 174:736-742
- 424 28. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the 425 lifespan: a meta-analysis. Diabetes Care 2008;31:2383-2390
- 426 29. Gallo JJ, Anthony JC, Muthén BO. Age differences in the symptoms of depression: a latent 427 trait analysis. J Gerontol 1994;49:P251-P264
- 428 30. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and 429 stress. J Psychosom Res 2002;53:865-871
- 430 31. Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance:
- 431 focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am 432 2014;43:75-102
- 433 32. Tabák AG, Akbaraly TN, Batty GD, Kivimäki M. Depression and type 2 diabetes: a causal 434 association? Lancet Diabetes Endocrinol 2014;2:236-245
- 435 33. Barth E, Albuszies G, Baumgart K, Matejovic M, Wachter U, Vogt J, Radermacher P, Calzia
- 436 E. Glucose metabolism and catecholamines. Crit Care Med 2007;35:S508-S518
- 437 34. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA. Sedentary
- 438 time and its association with risk for disease incidence, mortality, and hospitalization in adults:
- 439 a systematic review and meta-analysis. Ann Intern Med 2015;162:123-132
- 440 35. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants
- 441 and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and
- 442 bipolar disorder. World Psychiatry 2015;14:119-136
- 443 36. Diaz FJ, James D, Botts S, Maw L, Susce MT, De Leon J. Tobacco smoking behaviors in

- 444 bipolar disorder: a comparison of the general population, schizophrenia, and major depression.
- 445 Bipolar Disord 2009;11:154-165
- 446 37. Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC. Smoking and 447 major depression. A causal analysis. Arch Gen Psychiatry 1993;50:36-43
- 448 38. Xuan L, Zhao Z, Jia X, Hou Y, Wang T, Li M, Lu J, Xu Y, Chen Y, Qi L, Wang W. Type 2
- 449 diabetes is causally associated with depression: a Mendelian randomization analysis. Front
- 450 Med 2018;12:678-687
- 451 39. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample
- 452 Mendelian randomization. Genet Epidemiol 2016;40:597-608
- 453 40. Li Z, Chen P, Chen J, Xu Y, Wang Q, Li X, Li C, He L, Shi Y. Glucose and insulin-related
- 454 traits, type 2 diabetes and risk of schizophrenia: a Mendelian randomization study.
- 455 EBioMedicine 2018;34:182-188

456

457

458

No.	Exposure	Outcome	Ν	F-stat	I ² (%)	Q-test	Q'-test	MR-PRESSO global test
1	BPD	trme 2	11	32.9	96.9	0.718	0.821	0.695
2	MDD	type 2	42	37.9	97.3	0.808	0.788	0.733
3	SCZ	diabetes	72	41.5	97.6	0.319	0.290	0.704
4	type 2 diabetes	BPD	35	35.8	97.3	0.684	0.639	0.598
5		MDD	39	36.0	97.3	0.714	0.683	0.711
6		SCZ	43	35.8	97.2	< 0.001	< 0.001	< 0.001

 \overline{N} = Number of instruments, F-stat = F statistics, Q-test = P-value for the Q-test from IVW, Q'-test 461 = *P*-value for the Q'-test from MR-Egger, MR-PRESSO global test = *P*-value for MR-PRESSO global 462 test, BPD = bipolar disorder, MDD = major depressive disorder, SCZ = schizophrenia, MR-463 PRESSO = MR-Pleiotropy RESidual Sum and Outlier 464

MR methods	parameter	Ν	OR	95% CI	Р	Power
1. Effect of BPD on type	2 diabetes					
IVW	Estimate	11	1.006	[0.918, 1.104]	0.892	2.5%
MR-Egger	Intercept		1.039	[0.985, 1.095]	0.165	100%
	Slope		0.681	[0.389, 1.191]	0.178	-
MR-Egger (SIMEX)	Intercept		1.003	[1.010, 1.994]	0.540	2.1%
	Slope		0.995	[0.908, 1.089]	0.917	-
Weighted median	Estimate		0.982	[0.868, 1.111]	0.770	13.8%
MR-PRESSO	Estimate			No outlier	-	-
2. Effect of MDD on typ	e 2 diabetes					
IVW	Estimate	42	1.191	[1.036, 1.372]	0.014	100%
MR-Egger	Intercept		1.007	[0.982, 1.033]	0.566	74%
	Slope		0.934	[0.402, 2.172]	0.875	-
MR-Egger (SIMEX)	Intercept		1.004	[1.000, 1.008]	0.036	100%
	Slope		1.162	[1.024, 1.318]	0.025	-
Weighted median	Estimate		1.196	[0.984, 1.453]	0.072	100%
MR-PRESSO	Estimate			No outlier	-	-
3. Effect of SCZ on type	2 diabetes					
IVW	Estimate	72	1.016	[0.974, 1.059]	0.463	10.9%
MR-Egger	Intercept		1.000	[0.987, 1.014]	0.969	6.5%
	Slope		1.012	[0.851, 1.204]	0.888	-
MR-Egger (SIMEX)	Intercept		1.001	[0.998, 1.004]	0.427	9.6%
,	Slope		1.015	[0.981, 1.060]	0.511	-
Weighted median	Estimate		1.016	[0.955, 1.081]	0.615	10.9%
MR-PRESSO	Estimate			No outlier	-	-

Table 2. Mendelian randomization results 466

N = Number of instruments, BPD = bipolar disorder, MDD = major depressive disorder, SCZ467 = schizophrenia, MR = Mendelian randomization, IVW = inverse-variance weighted, MR-468 PRESSO = MR-Pleiotropy RESidual Sum and Outlier, SIMEX = simulation extrapolation, OR 469 470 = odds ratio

MR methods	parameter	Ν	OR	95% CI	Р	Power
1. Effect of type 2 diabet	tes on BPD					
IVW	Estimate	35	1.031	[0.971, 1.095]	0.313	18.9%
MR-Egger	Intercept		0.998	[0.974, 1.022]	0.890	52.7%
	Slope		1.051	[0.793, 1.394]	0.727	-
MR-Egger (SIMEX)	Intercept		0.997	[0.989, 1.004]	0.428	2.1%
	Slope		0.993	[0.909, 1.083]	0.867	-
Weighted median	Estimate		1.041	[0.956, 1.134]	0.349	34.3%
MR-PRESSO	Estimate			No outlier	-	-
2. Effect of type 2 diabet	tes on MDD					
IVW	Estimate	39	1.002	[0.985, 1.020]	0.793	2.2%
MR-Egger	Intercept		0.999	[0.994, 1.005]	0.852	18.6%
	Slope		1.008	[0.949, 1.070]	0.798	-
MR-Egger (SIMEX)	Intercept		1.001	[0.999, 1.002]	0.278	2.2%
	Slope		1.002	[0.985, 1.019]	0.808	-
Weighted median	Estimate		1.007	[0.982, 1.033]	0.581	14%
MR-PRESSO	Estimate			No outlier	-	-
3. Effect of type 2 diabet	tes on SCZ					
IVW	Estimate	43	1.006	[0.939, 1.075]	0.872	2.2%
MR-Egger	Intercept		0.997	[0.974, 1.019]	0.783	50.1%
	Slope		1.040	[0.806, 1.343]	0.758	-
MR-Egger (SIMEX)	Intercept		1.003	[0.997, 1.009]	0.246	3.3%
	Slope		1.009	[0.941, 1.082]	0.785	-
Weighted median	Estimate		0.980	[0.914, 1.050]	0.564	12.4%
MR-PRESSO	Estimate	41	0.999	0.991, 1.009	0.987	1%

472	Table 3. Bi-directional Mendelian randomization results

N = Number of instruments, BPD = bipolar disorder, MDD = major depressive disorder, SCZ 473

= schizophrenia, MR = Mendelian randomization, IVW = inverse-variance weighted, MR-474

PRESSO = MR-Pleiotropy RESidual Sum and Outlier, SIMEX = simulation extrapolation, OR 475 = odds ratio 476

FIGURE LEGEND

Figure 1. Scatter plots showing the associations of the genetic variants with psychiatric disorders and type 2 diabetes for different methods of Mendelian randomization. (A) The associations of the variants with BPD and type 2 diabetes. (B) The associations of the variants with MDD and type 2 diabetes. (C) The associations of the variants with SCZ and type 2 diabetes.

Abbreviations: BPD = bipolar disorder, MDD = major depressive disorder, SCZ = schizophrenia, MR = Mendelian randomization, IVW = inverse-variance weighted, SIMEX = simulation extrapolation



medRxiv preprint doi: https://doi.org/10.1101/2020.09.12.20193060; this version posted September 12, 2020. The copyright holder for this SUICE preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.